Learn more about Invea and the team that is making a difference.
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
– Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology
– Company also primed to advance additional programs, including a pan-inflammasome inhibitor
Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode the gut-brain axis, innate immunity, and neuroinflammation for target identification and drug discovery
Decoding the Mechanisms that Drive Chronic Inflammation to Develop Medicines for Immune-Mediated Inflammatory Disorders
Decoding the Mechanisms that Drive Chronic Inflammation to Develop Medicines for Immune-Mediated Inflammatory Disorders
© 2023 Invea Therapeutics, Inc. All rights reserved | Privacy Policy | Disclaimer
